HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of recurrent vulvo-vaginal candidiasis with sustained-released butoconazole pessary.

Abstract
Vulvo-vaginal candidiasis (VVC) is a common infection among women. 5% of women with acute infection experience recurrent vulvo-vaginal candidiasis (RVVC). There is currently no optimal or recommended regime for RVVC. Although antifungal agents, such as imidazoles, have been successfully used as a first-line treatment for acute VVC, its effectiveness is limited in RVVC. This could be due to patient factors, drug application (such as leakage) or dosing factors. A sustained-release (SR) bioadhesive vaginal cream (2% butoconazole nitrate) has incorporated VagiSite technology, a topical drug delivery system that allows SR of the drug. We describe its efficacy and the successful use of a butoconazole-SR formulation in the treatment of two cases of RVVC.
AuthorsLing Zhi Heng, Yujia Chen, Thiam Chye Tan
JournalSingapore medical journal (Singapore Med J) Vol. 53 Issue 12 Pg. e269-71 (Dec 2012) ISSN: 0037-5675 [Print] India
PMID23268172 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antifungal Agents
  • Imidazoles
  • butoconazole
Topics
  • Adult
  • Antifungal Agents (administration & dosage)
  • Candidiasis, Vulvovaginal (drug therapy)
  • Female
  • Humans
  • Imidazoles (administration & dosage)
  • Middle Aged
  • Pessaries
  • Recurrence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: